Browsing by author "Roulstone, Victoria"
Now showing items 1-14 of 14
-
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to ... -
Biological effects of combination therapy with oncolytic reovirus and palbociclib
Roulstone, V (Institute of Cancer Research (University Of London), 2021-09-30)Reovirus type 3 Dearing (RtD3) is an oncolytic dsRNA virus with limited single-agent activity in clinical studies but has potential for use in combination regimens. Herein, I sought to discover synergistic drug-virotherapy ... -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova, G; Hassan, J; Appleton, L; Jennings, V; Foo, S; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology ... -
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; et al. (TAYLOR & FRANCIS LTD, 2020-06-02)Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ... -
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas, S; Kuncheria, L; Roulstone, V; Kyula, JN; Mansfield, D; et al. (BMJ PUBLISHING GROUP, 2019-08-10)BACKGROUND: Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development ... -
Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.
McEntee, G; Kyula, JN; Mansfield, D; Smith, H; Wilkinson, M; et al. (IMPACT JOURNALS LLC, 2016-07-26)Oncolytic viruses selectively target and replicate in cancer cells, providing us with a unique tool with which to target and kill tumour cells. These viruses come from a diverse range of viral families including reovirus ... -
Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.
Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-24)Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ... -
Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.
Wilkinson, MJ; Smith, HG; Pencavel, TD; Mansfield, DC; Kyula-Currie, J; et al. (WILEY, 2016-09-15)The management of locally advanced or recurrent extremity sarcoma often necessitates multimodal therapy to preserve a limb, of which isolated limb perfusion (ILP) is a key component. However, with standard chemotherapeutic ... -
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield, DC; Kyula, JN; Rosenfelder, N; Chao-Chu, J; Kramer-Marek, G; et al. (NATURE PUBLISHING GROUP, 2016-04-01)Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy ... -
Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis.
Wilkinson, MJ; Smith, HG; McEntee, G; Kyula-Currie, J; Pencavel, TD; et al. (IMPACT JOURNALS LLC, 2016-12-06)Advanced extremity melanoma and sarcoma present a significant therapeutic challenge, requiring multimodality therapy to treat or even palliate disease. These aggressive tumours are relatively chemo-resistant, therefore new ... -
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith, HG; Mansfield, D; Roulstone, V; Kyula-Currie, JN; McLaughlin, M; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor monotherapy has shown little activity in sarcoma and there is great interest in identifying novel ... -
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
Smith, HG; Jamal, K; Dayal, JH; Tenev, T; Kyula-Currie, J; et al. (WILEY, 2020-06-08)Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ... -
Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins, C; Simpson, GR; Rogers, W; Relph, K; Harrington, K; et al. (NATURE PUBLISHING GROUP, 2018-05-01)There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress ... -
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
McLaughlin, M; Pedersen, M; Roulstone, V; Bergerhoff, KF; Smith, HG; et al. (CELL PRESS, 2020-03-27)Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...